Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125